MAH and D-MAH in Japan: What Overseas Companies Need to Know
Entering the Japanese healthcare market is a strategic milestone for global pharmaceutical and medical device companies. However, navigating the country’s strict regulatory framework requires a clear understanding of domestic legal obligations. Under Japan’s Pharmaceuticals and Medical Devices Act (PMD Act), no therapeutic product can be marketed without a designated entity held legally responsible for its quality, safety, and regulatory compliance within the country [1].
For overseas companies without a local Japanese entity, selecting the right partner to serve as a Marketing Authorization Holder (MAH) or Designated Marketing Authorization Holder (D-MAH) is a critical decision. As a proud member of the Alfresa Group, ArkMS supports with a variety of pathways for Japan. Through Alfresa’s comprehensive “PATH-Solution”, we offer end-to-end support combining regulatory sponsorship, commercial manufacturing support, and nationwide GDP-compliant distribution-ensuring a seamless transition from product approval to commercial success in Japan [4].
* PATH Solution | Alfresa Holdings Corporation
What Is an MAH in Japan?
In Japan, marketing approval for a pharmaceutical product or medical device is not granted in a vacuum; it must be tied directly to an established, licensed entity known as a Marketing Authorization Holder (MAH) [1]. The MAH serves as the legal licensee responsible for bringing the product to market and maintaining its ongoing safety and quality compliance.
MAH Responsibilities: Quality, Safety, and Post-Marketing Duties
An MAH is not merely an administrative contact or a submission proxy; it is a continuously active, legally binding entity that carries ultimate responsibility for the product throughout its entire commercial lifecycle [1]. The core duties of an MAH include:
- Quality Assurance (GQP): Enforcing Good Quality Practice (GQP) standards to ensure that all imported and distributed products strictly meet approved release specifications.
- Post-Marketing Safety Management (GVP): Operating under Good Vigilance Practice (GVP) to collect, evaluate, and report adverse events to the PMDA and MHLW [2].
- Regulatory Liaison: Managing ongoing communication with Japanese regulatory bodies, including handling post-approval variations, license renewals, and official inspections.
- Supply Chain Oversight: Ensuring that manufacturing sites (both domestic and foreign) adhere to Japanese Good Manufacturing Practice (GMP) regulations.
MAH vs D-MAH in Japan
Overseas companies seeking market access in Japan generally face a fundamental choice: establish a local subsidiary to act as the MAH or leverage the Designated Marketing Authorization Holder (D-MAH) system.
How D-MAH Works for Overseas Companies
The D-MAH system was introduced to allow foreign manufacturers-who retain the product ownership rights as the Foreign Special Approval Holder (FSAH)-to market their products in Japan without incorporating a local legal subsidiary [1]. Under this arrangement:
- The overseas company holds the ultimate product approval.
- The appointed D-MAH handles all local regulatory, quality (GQP), and safety (GVP) duties within Japan on behalf of the foreign holder.
- The D-MAH serves as the official point of contact for the PMDA and MHLW, fulfilling all legal requirements while allowing the foreign sponsor to maintain global ownership of the intellectual property and approval asset.
MAH and D-MAH Comparison
| Feature / Criteria | Japanese Subsidiary (MAH) | Designated MAH (D-MAH) | Third-Party MAH |
| Approval Holder | Local Subsidiary | Overseas Company (FSAH) | Third-Party Entity |
| Local Regulatory Responsibility | Fully Assumed by Subsidiary | Managed by D-MAH Proxy | Fully Transferred to Third Party |
| Capital & Operational Overhead | Very High (Office, Staff, Licenses) | Low (Service Contract Basis) | Low (Product Rights Often Transferred) |
| Control over Intellectual Property | Full Control (Internal) | High Control (Sponsor Retains Asset) | Limited Control |
| Time to Market | Slow (1–2+ Years to Set Up) | Fast (Immediate Licensing Access) | Fast |
| Commercial Flexibility | High | High (Easy to Switch Partners) | Low (Asset Tied to Partner) |
Choosing the Right Japan Market Entry Model
When planning market entry into Japan, biopharma and medical device companies must evaluate three main models based on their long-term corporate strategy, resource availability, and risk tolerance.
Japanese Subsidiary, D-MAH, or Third-Party MAH
- Establishing a Japanese Subsidiary (MAH): Gives the company complete operational control and brand presence. However, this model requires massive capital investment, complex legal setup, and years of effort to secure local GQP/GVP licenses and hire specialized staff.
- Appointing a D-MAH Partner: The optimal solution for emerging biopharma companies. It drastically reduces market entry time and overhead costs while allowing the foreign sponsor to retain product approval ownership and commercial flexibility.
- Out-Licensing to a Third-Party MAH: The foreign company transfers the marketing rights to an established Japanese pharmaceutical partner. While this minimizes financial risk, it sacrifices long-term strategic control and profit margins.
Pharmaceuticals vs. Medical Devices
While both pharmaceuticals and medical devices require an MAH/D-MAH structure in Japan, the specific regulatory pathways, classification systems, and GQP/GVP enforcement details differ significantly between the two categories under the PMD Act [1, 3]. Partnering with an experienced specialist ensures that category-specific requirements—such as device maintenance standards or drug stability monitoring—are fully addressed.
How to Choose an MAH / D-MAH Partner
Selecting the right MAH/D-MAH partner is one of the most strategic decisions an overseas company can make. Beyond basic regulatory compliance, an ideal partner should offer comprehensive infrastructure capable of supporting the entire commercial journey.
Key evaluation criteria include:
- Regulatory & PMDA Expertise: Proven track record in conducting successful PMDA consultations, J-NDA submissions, and agency audit responses.
- Robust Quality & Safety Systems: Fully compliant GQP and GVP management structures staffed by experienced local officers.
- Commercial & Supply Chain Capability: The ability to move beyond paper compliance and support real-world manufacturing, warehousing, and nationwide distribution.
The ArkMS & Alfresa Advantage: Comprehensive “PATH-Solution”
This is where ArkMS provides a unique competitive edge. As part of the Alfresa Group—one of Japan’s premier healthcare groups—ArkMS does not treat MAH/D-MAH representation as an isolated administrative function [4].
Through Alfresa’s PATH-Solution (Platform for Accelerating Therapeutics in Healthcare), ArkMS offers an integrated, one-stop ecosystem [4]:
- End-to-End Regulatory & MAH/D-MAH Support: ArkMS acts as your local regulatory representative, managing all PMDA/MHLW communications, GQP quality assurance, and GVP post-marketing surveillance [4]. Moreover, we can explore MAH/D-MAH options for Japan with you.
- Manufacturing Integration: Leveraging the Alfresa Group’s extensive commercial manufacturing capabilities, we can ensure seamless technology transfer, batch release, and local packaging compliance for certain product areas.
- Nationwide GDP Distribution: Once authorized, your therapeutic products instantly connect into the Alfresa Group’s unparalleled, nationwide distribution network, ensuring safe, temperature-controlled delivery to hospitals, clinics, and pharmacies across all of Japan [4].
Key Takeaways on MAH Japan
Establishing a compliant MAH or D-MAH framework is an essential legal prerequisite for commercializing pharmaceuticals and medical devices in Japan. For foreign sponsors without a local subsidiary, appointing a highly qualified D-MAH partner offers the fastest, most cost-effective path to market while preserving core asset ownership [1].
By choosing ArkMS, overseas companies gain more than a regulatory proxy—they unlock the full strength of the Alfresa Group. From early regulatory strategy and D-MAH management to commercial-scale manufacturing and nationwide distribution, ArkMS’s PATH-Solution provides the total ecosystem required to bring your life-saving therapies to Japanese patients efficiently, compliantly, and successfully [4].
References
- [1] Ministry of Health, Labour and Welfare (MHLW). Approval and Licensing System for Pharmaceuticals and Medical Devices. Retrieved from https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/01.html
- [2] Pharmaceuticals and Medical Devices Agency (PMDA). Safety Information and GVP Standards. Retrieved from https://www.pmda.go.jp/english/safety/info-services/0001.html
- [3] Pharmaceuticals and Medical Devices Agency (PMDA). Medical Devices Regulations. Retrieved from https://www.pmda.go.jp/english/review-services/reviews/0004.html
- [4] ArkMS. Global Services & Integrated Solutions. Retrieved from https://www.arkms.co.jp/english/service/global/